Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...

PRINCETON, NJ and TOKYO, JAPAN, November 20, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...

TOKYO, JAPAN and PRINCETON, NJ, Nov. 6, 2007 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved ...

Bristol-Myers Squibb and Otsuka have introduced two new formulations of their antipsychotic medication Abilify in the USA, to make it easier for doctors to dose patients effectively. Bristol-Myers ...

The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

Co confirmed that it has initiated a challenge of the patent listed by Otsuka Pharmaceutical Co., Ltd in connection with its Abilify (aripiprazole) tablets, 2mg, 5mg, 10mg, 15mg, 20mg & 30mg.